Andrea Laslop

Andrea Laslop

Auto-generated profile, based on publicly available information

Andrea Laslop

Scientific Office, Federal Office for Safety in Health Care, Vienna, Austria

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 March 2025 in Osteoporosis International
Verified
Journal Article
Open access
PDF file
HBHarjit Pal Bhattoa
Harjit Pal Bhattoa
SVSamuel Vasikaran
Samuel Vasikaran
ITIoulia Trifonidi
Ioulia Trifonidi
GKGeorgia Kapoula
Georgia Kapoula
Giovanni LombardiGiovanni Lombardi
Giovanni Lombardi
ECEtienne Cavalier
Etienne Cavalier
Purpose The International Osteoporosis Foundation (IOF) and the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) have proposed procollagen type I N propeptide (PINP) and β isomerized C-terminal telopeptide of type I collagen (β-CTX-I) as reference bone turnover markers (BTMs) for osteoporosis. This report examines the published literature since the 2011 IOF-IFCC position paper in order to determine the clinical potential of the reference BTMs and newer markers for the prediction of fracture risk and monitoring the treatment of osteoporosis. Methods Evidence for the relationship between BTMs and subsequent fractures was gathered from prospective studies through literature review of the Medline database from years 2011 to May 2024. The impact of treatment on BTMs was also studied by examining publications in that period. Studies of the accuracy of BTMs in the assessment of bone turnover in the setting of advanced chronic kidney disease were also examined. Results Increased BTM concentrations are associated with higher fracture risk in postmenopausal women. PINP and β-CTX-I measured in blood are associated with fracture risk but their interaction with other risk factors has not been sufficiently studied limiting their incorporation into fracture risk algorithms. Treatment-induced changes in PINP and β-CTX-I account for a substantial proportion of fracture risk reduction and are useful for improving adherence; they are recommended for inclusion in studies to examine adherence in individual patients. However, total PINP (tPINP) and β-CTX-I may be elevated in CKD due to renal retention. Bone alkaline phosphatase (BALP), intact PINP (iPINP), and tartrate resistant acid phosphatase 5b (TRACP5b) show the most promise in discriminating high and low turnover bone diseases in patients with advanced CKD and for predicting fracture risk, monitoring treatment response, and assessing the risk of treatment-related complications. Conclusion We re-affirm the use of serum/plasma tPINP and plasma β-CTX-I as reference BTMs with appropriate patient preparation and sample handling and measurement by standardized/harmonized assays in clinical studies to accumulate further data, and for monitoring treatment of osteoporosis in the setting of normal renal function in clinical practice. BALP and TRACP5b, measured by standardized assays, are recommended as reference BTMs for CKD-associated osteoporosis and should be included in observational and intervention studies to ascertain their utility for risk-evaluation, treatment initiation, and assessment of treatment response in CKD-associated osteoporosis.

14 March 2024 in Nature Reviews Rheumatology
Verified
Journal Article
Open access
PDF file
NFNicholas Fuggle
Nicholas Fuggle
CBCharlotte Beaudart
Charlotte Beaudart
OBOlivier Bruyère
Olivier Bruyère
BABo Abrahamsen
Bo Abrahamsen
NANasser Al-Daghri
Nasser Al-Daghri
NHNicholas C. Harvey
Nicholas C. Harvey
Historically, osteoporosis has been viewed as a disease of women, with research, trials of interventions and guidelines predominantly focused as such. It is apparent, however, that this condition causes a substantial health burden in men also, and that its assessment and management must ultimately be addressed across both sexes. In this article, an international multidisciplinary working group of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases presents GRADE-assessed recommendations for the diagnosis, monitoring and treatment of osteoporosis in men. The recommendations are based on a comprehensive review of the latest research related to diagnostic and screening approaches for osteoporosis and its associated high fracture risk in men, covering disease burden, appropriate interpretation of bone densitometry (including the use of a female reference database for densitometric diagnosis in men) and absolute fracture risk, thresholds for treatment, and interventions that can be used therapeutically and their health economic evaluation. Future work should specifically address the efficacy of anti-osteoporosis medications, including denosumab and bone-forming therapies.

3 October 2025 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
PDF file
NFNicholas Fuggle
Nicholas Fuggle
RCRoland Chapurlat
Roland Chapurlat
ALAndrea Laslop
Andrea Laslop
NANasser Al-Daghri
Nasser Al-Daghri
MAMajed Alokail
Majed Alokail
NHNicholas C. Harvey
Nicholas C. Harvey

27 December 2024 in Aging Clinical and Experimental Research
Verified
Journal Article
Open access
PDF file
ECElizabeth M. Curtis
Elizabeth M. Curtis
MRMario Miguel Rosa
Mario Miguel Rosa
CMClaire McEvoy
Claire McEvoy
ATAndrea Ticinesi
Andrea Ticinesi
CTCarla Torre
Carla Torre
NHNicholas C. Harvey
Nicholas C. Harvey
Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored. Discussion will focus on how changes in brain and bone signalling can underly associations between these conditions, and will consider the molecular and cellular drivers in the context of inflammation and the gut microbiome. There is a complex interplay between nutritional changes, which may precede or follow the onset of mild cognitive impairment (MCI) or dementia, and bone health. Polypharmacy is common in patients with MCI or dementia, and there are difficult prescribing decisions to be made due to the elevated risk of falls associated with many drugs used for associated problems, which can consequently increase fracture risk. Some medications prescribed for cognitive impairment may directly impact bone health. In addition, patients may have difficulty remembering medication without assistance, meaning that osteoporosis drugs may be prescribed but not taken. Cognitive impairment may be improved or delayed by physical activity and exercise, and there is evidence for the additional benefits of physical activity on falls and fractures. Research gaps and priorities with the aim of reducing the burden of osteoporosis and fractures in people with MCI or dementia will also be discussed.

15 June 2016 in Generics and Biosimilars Initiative Journal
Verified
Journal Article
Open access
VAVito Annese
Vito Annese
CACristina Avendaño-Solá
Cristina Avendaño-Solá
FBFerdinand Breedveld
Ferdinand Breedveld
NENiklas Ekman
Niklas Ekman
TGThijs J Giezen
Thijs J Giezen
EWElena Wolff-Holz
Elena Wolff-Holz
Authors byline as per print journal:Vito Annese, MD, PhD; Cristina Avendaño-Solá, MD, PhD; Professor Ferdinand Breedveld, MD; Niklas Ekman, PhD; Thijs J Giezen,

16 November 2026 in Nature Reviews Rheumatology
Verified
Journal Article
Closed access
LWLeo David Westbury
Leo David Westbury
ECElizabeth M. Curtis
Elizabeth M. Curtis
EBEwa Balkowiec-Iskra
Ewa Balkowiec-Iskra
ACAntonio Cherubini
Antonio Cherubini
MRMario Miguel Rosa
Mario Miguel Rosa
Jean-Yves ReginsterJean-Yves Reginster
Jean-Yves Reginster